Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells

Oncotarget

Volumn 7, Issue 52, 2016, Pages 86446-86456

  Liu, Jiajia ^a   Tang, Qinglai ^a   Li, Shisheng ^a   Yang, Xinming ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; HAX 1; Laryngeal cancer stem cells; MicroRNA 125a

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 125A; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; HAX1 PROTEIN, HUMAN; MIRN125 MICRORNA, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HAX 1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; LARYNGEAL CANCER CELL LINE; LARYNX CANCER; LARYNX CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; LARYNX TUMOR; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, INBRED BALB C; MICRORNAS; MITOCHONDRIA; NEOPLASTIC STEM CELLS;

EID: 85007471051     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13424     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30
2. Ferlito A, Haigentz M Jr, Bradley PJ, Suarez C, Strojan P, Wolf GT, Olsen KD, Mendenhall WM, Mondin V, Rodrigo JP, Boedeker CC, Hamoir M, Hartl DM, et al. Causes of death of patients with laryngeal cancer. European archives of oto-rhino-laryngology. 2014; 271:425-434
3. Belcher R, Hayes K, Fedewa S, Chen AY. Current treatment of head and neck squamous cell cancer. Journal of surgical oncology. 2014; 110:551-574
4. Huang J, Zhou L, Chen H, Wu C, Duo Z, Zhang Y. EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells. Oncol Lett. 2016; 12:837-846
5. Liang DP, Huang TQ, Li SJ, Chen ZJ. Knockdown of S100A4 chemosensitizes human laryngeal carcinoma cells in vitro through inhibition of Slug. Eur Rev Med Pharmacol Sci. 2014; 18:3484-3490
6. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stemcells versus clonal evolution. Cell. 2009; 138:822-829
7. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006; 124:1111-1115
8. Xudong Wei, Jingyu Wang, Jian He, Bingjuan Ma, Jing Chen. Biological characteristics of CD133+ cancer stem cells derived from human laryngeal carcinoma cell line. Int J Clin Exp Med. 2014; 7:2453-2462
9. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009; 8:158-166
10. Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD 133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One. 2009; 4:e5395
11. Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, Wang X, Keng P, Lee SO. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat Oncol. 2015; 10:227
12. Gargalionis AN, Basdra EK. Insights in microRNAs biology. Curr Top Med Chem. 2013; 13:1493-1502
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297
14. Esteller M. Non-coding RNAs in human disease. Nature reviews Genetics. 2011; 12:861-874
15. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113:673-676
16. Iorio MV and Croce CM. MicroRNA involvement in human cancer. Carcinogenesis. 2012; 33:1126-1133
17. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215-233
18. Xu CZ, Xie J, Jin B, Chen XW, Sun ZF, Wang BX, Dong P. Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line. Int J Clin Exp Pathol. 2013; 6: 1351-1361
19. Radhika V, Onesime D, Ha JH, Dhanasekaran N. Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1. J Biol Chem. 2004; 279:49406-49413
20. E Khoury F, Corcos L, Durand S, Simon B, Le Jossic-Corcos C. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells. Int J Oncol. 2016
21. Zhan Y, Mou L, Cheng K, Wang C, Deng X, Chen J, Fan Z, Ni Y. Hepatocellular carcinoma stem cell-like cells are enriched following low-dose 5-fluorouracil chemotherapy. Oncol Lett. 2016; 12:2511-2516
22. Vicari L, Colarossi C, Giuffrida D, De Maria R, Memeo L. Cancer stem cells as a potential therapeutic target in thyroid carcinoma. Oncol Lett. 2016; 12:2254-2260
23. Rosa R, D'Amato V, De Placido S, Bianco R. Approaches for targeting cancer stem cells drug resistance. Expert Opin Drug Discov. 2016
24. Yang J, Guo W, Wang L, Yu L, Mei H, Fang S, Ji P, Liu Y, Liu G, Song Q. Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model. Oncol Lett. 2016; 12:2599-2605
25. Majidinia M, Yousefi B. DNA damage response regulation by microRNAs as a therapeutic target in cancer. DNA Repair (Amst). 2016; S1568-7864: 30337-30338
26. Riquelme I, Letelier P, Riffo-Campos AL, Brebi P, Roa JC. Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer. Int J Mol Sci. 2016; 17:424
27. Fan Z, Cui H, Yu H, Ji Q, Kang L, Han B, Wang J, Dong Q, Li Y, Yan Z, Yan X, Zhang X, Lin Z, Hu Y, Jiao S. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis. 2016; 5:e197
28. Xu X, Lv YG, Yan CY, Yi J, Ling R. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. Biochem Biophys Res Commun. 2016; 479:893-900
29. Suzuki Y, Demoliere C, Kitamura D, Takeshita H, Deuschle U, Watanabe T. HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol. 1997; 158:2736-2744
30. Chao JR, Parganas E, Boyd K, Hong CY, Opferman JT, Ihle JN. Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons. Nature. 2008; 452:98-102
31. Trebinska A, Rembiszewska A, Ciosek K, Ptaszynski K, Rowinski S, Kupryjanczyk J, Siedlecki JA, Grzybowska EA. HAX-1 overexpression, splicing and cellular localization in tumors. BMC Cancer. 2010; 10:76
32. Trebinska A, Högstrand K, Grandien A, Grzybowska EA, Fadeel B. Exploring the anti-apoptotic role of HAX-1 versus BCL-XL in cytokine-dependent bone marrowderived cells from mice. FEBS Lett. 2014; 588:2921-2927
33. Yan J, Ma C, Cheng J, Li Z, Liu C. HAX-1 inhibits apoptosis in prostate cancer through the suppression of caspase-9 activation. Oncol Rep. 2015; 34:2776-2781
34. Ma J, Zhao Z, Wu K, Xu Z, Liu K. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. Gene. 2016; 587:147-154
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25:402-408
36. Prathapan A, Vineetha VP, Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One. 2014; 9:e96220
37. Zhao Z, Lu P, Zhang H, Xu H, Gao N, Li M, Liu C. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res. 2014; 16:408